Literature DB >> 12711114

Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types.

Wei-Min Gao1, Hussam H Mady, Guo-Ying Yu, Jill M Siegfried, James D Luketich, Mona F Melhem, Phouthone Keohavong.   

Abstract

The p53 gene is frequently mutated in lung tumors, and mutations may be caused by both polycyclic aromatic hydrocarbons (PAHs) and nitrosamines found in tobacco smoke. The two major forms of lung cancer, adenocarcinoma (AC) and squamous cell carcinoma (SCC), are known to differ in the proportion of tumors exhibiting p53 mutation, and may also differ in the mutational spectra produced. Previous studies comparing p53 mutational spectra between AC and SCC of the lung have been limited by small sample size. We examined p53 mutations in exons 5-8 in 202 cases of AC and 82 cases of SCC from smoking lung cancer patients in the Western Pennsylvania region. The percent of cases with p53 mutation was significantly lower in ACs (40/202, 20%) compared to SCCs (29/82, 35%, P=0.006). The proportion of mutations present that were G to T transversions was not significantly different between the two tumor types (52% of p53 mutations in AC compared to 32% in SCC). G to A transitions either did not differ in frequency in the two types of lung cancer (20% of mutations in AC and 24% of mutations in SCC). A distinct spectrum was observed, however, in the p53 mutation pattern in the two types of lung cancer. ACs showed a strong preference for a mutational hotspot at codons 248 and 249, while squamous cell tumors showed mutational events spread throughout exons 5-8, with a preference for codon 267. Mutations at codon 267 in SCC were all C to T transitions that occurred at CpG sites. Both tumor types demonstrated preferential mutation of the non-transcribed strand (100% of all G to T transversions and 55% of the G to A transitions). These results suggest that p53 mutations in both types of lung tumors may arise from adduction by both PAHs and nitrosamines. Mutations arising in ACs appear selectively in regions of p53 that produce more rigid proteins, suggesting a drastic change in p53 function is needed to result in ACs, while less constrained changes in p53 function can result in SCCs. Mutation in p53 was not found to be related to patient survival in this group of patients, while tumor size and degree of differentiation were poor survival predictors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12711114     DOI: 10.1016/s0169-5002(03)00035-7

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

1.  Large cell lung carcinoma with unusual imaging feature, immunophenotype and genetic finding.

Authors:  Jelena Stojsic; Ruza Stevic; Milica Kontic; Zorica Stojsic; Neda Drndarevic; Vera Bunjevacki; Biljana Jekic
Journal:  Pathol Oncol Res       Date:  2010-04-21       Impact factor: 3.201

2.  Racial diversity of actionable mutations in non-small cell lung cancer.

Authors:  Aliccia Bollig-Fischer; Wei Chen; Shirish M Gadgeel; Angela S Wenzlaff; Michele L Cote; Ann G Schwartz; Gerold Bepler
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 15.609

3.  Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk.

Authors:  Weimin Gao; Marjorie Romkes; Shilong Zhong; Tomoko Nukui; Raj A Persad; Patrick J B Smith; Robert Branch; Phouthone Keohavong
Journal:  Oncol Rep       Date:  2010-07       Impact factor: 3.906

Review 4.  Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer.

Authors:  Alphy Rose-James; Sreelekha Tt
Journal:  Lung Cancer Int       Date:  2012-09-19

5.  Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.

Authors:  Yang Liu; Weimin Gao; Jill M Siegfried; Joel L Weissfeld; James D Luketich; Phouthone Keohavong
Journal:  BMC Cancer       Date:  2007-05-03       Impact factor: 4.430

6.  The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.

Authors:  Michael Bergqvist; Daniel Brattström; Anders Larsson; Patrik Hesselius; Ola Brodin; Gunnar Wagenius
Journal:  BMC Cancer       Date:  2004-09-14       Impact factor: 4.430

7.  A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect.

Authors:  Yunguang Sun; Carey Jeanne Myers; Adam Paul Dicker; Bo Lu
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

8.  Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial.

Authors:  Yi Li; Long-Jiang Li; Li-Juan Wang; Zhuang Zhang; Ning Gao; Chen-Yuan Liang; Yuan-Ding Huang; Bo Han
Journal:  BMC Med       Date:  2014-01-30       Impact factor: 8.775

9.  Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma.

Authors:  Chenguang Li; Zhibo Gao; Fei Li; Xiangchun Li; Yihua Sun; Mengyun Wang; Dan Li; Rui Wang; Fuming Li; Rong Fang; Yunjian Pan; Xiaoyang Luo; Jing He; Liangtao Zheng; Jufeng Xia; Lixin Qiu; Jun He; Ting Ye; Ruoxin Zhang; Minghui He; Meiling Zhu; Haichuan Hu; Tingyan Shi; Xiaoyan Zhou; Menghong Sun; Shilin Tian; Yong Zhou; Qiaoxiu Wang; Longyun Chen; Guangliang Yin; Jingya Lu; Renhua Wu; Guangwu Guo; Yingrui Li; Xueda Hu; Lin Li; Qin Wang; Ye Yin; Qiang Feng; Bin Wang; Hang Wang; Mingbang Wang; Xiaonan Yang; Xiuqing Zhang; Huanming Yang; Li Jin; Cun-Yu Wang; Hongbin Ji; Haiquan Chen; Jun Wang; Qingyi Wei
Journal:  Sci Rep       Date:  2015-10-27       Impact factor: 4.379

10.  The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer.

Authors:  Zekiye Hasbek; Ömer Tamer Doğan; İsmail Sarı; Birsen Yücel; Mehmet Metin Şeker; Bülent Turgut; Serdar Berk; Yavuz Siliğ
Journal:  Mol Imaging Radionucl Ther       Date:  2016-10-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.